News

AB-Therapeutics Announces the Launch of its New Web Site www.ab-therapeutics.com

June 15, 2011

AB-Therapeutics SL, a clinical-stage pharmaceutical biotech company in early 2012, today announced the launch of its new Web site: www.ab-therapeutics.com. The new Web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about AB-Therapeutics’s business model, pipeline, partnerships and innovative technology.

“Our significant developments in the past year, including taking our first product into regulatory preclinical development, has opened new prospects for our company as we expect to initiate First in Man clinical trial as early as 1Q2012”. “This new site provides visitors an architecture that facilitates quick and efficient access to the information they need”, said Carles Domènech, PhD, Chief Executive Officer of AB-Therapeutics.

ABOUT AB-THERAPEUTICS

AB-Therapeutics is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
AB-Therapeutics develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a product ABT0812 in regulatory preclinical development, with Phase I clinical trials (first in man) starting early 2012. A second drug candidate ABT1014 will start preclinical development in 4Q2011.
Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com
 
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits